2nd Quarter - Report

ASSOCIATION FOR ACCESSIBLE MEDICINES for ASSOCIATION FOR ACCESSIBLE MEDICINES

Firm
Client
Income
—
Expenses
$500,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

5 issue areas, each in the filer's own words, with who lobbied on it and where.

Pharmacy PHA

Prescription Drug Costs. Drug Pricing. Civil Monetary Penalties. 180-Day Exclusivity. S.1114: Expanding Access to Low-Cost Generics Act of 2023. S.1128: Ensuring Access to Generic Medications Act. S.2129: Ensuring Access to Lower-Cost Medicines for Seniors Act. S.574: Increasing Prescription Drug Competition Act. Crenshaw Interchangeability and Bioequivalence Common Rating. H.R.1790: Biologics Competition Act of 2023. Labeling of Generic Drugs and Biosimilars. Hickenlooper Safe Harbor for Skinny Labeling. Generic Carveouts Patent Protected Information in Drug Labels Including Issues Related to GSK v. Teva. S.775: Increasing Transparency in Generic Drug Applications Act. Incentivize Domestic Manufacturing. Drug Shortages. Stockpile of Generic Drugs. GAO Report on Generic Drug Framework. Generic Drug User Fee Amendments (GDUFA). GDUFA III Negotiations. BsUFA III Negotiations. Biosimilars Insulin. Cost Sharing for Biosimilars. Same Strength Requirement for Biosimilars. Biosimilar Red Tape Eliminations Act. Expediting Competitive Biosimilar Competition. Crenshaw Competitive Biosimilar Therapy Bill. FDA Inspections. Shaheen-Sanders Inspections. Energy & Commerce Factory Inspection Legislation. FDA-PTO Collaboration. FDA Catalyst Decision. FDA Proposal on Combination Products. Shaheen-Cassidy Citizen Petition Legislation. Buy American Proposals. Inflation Reduction Act (IRA) Implementation. HELP Committee Briefing. H.R.3561: PATIENT Act of 2023. Trusted Partners in Medical Supply Chains.

LobbyistCovered position, as disclosed
CRAIG BURTON —
KARIN HESSLER —
PETER KELBEL —
KATHERINE RAAB —

Contacted: HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); Natl Economic Council (NEC); SENATE

Bills named: H.R. 1790 (118th), H.R. 3561 (118th), S. 775 (118th), S. 574 (118th), S. 2129 (118th), S. 1114 (118th), S. 1128 (118th)

Medicare/Medicaid MMM

Medicare Part D Reform. Medicare Part D Program and Generic Drugs. Medicare Part D Low Income Subsidy (LIS) Program. Medicare Part D Coverage Gap Discount Program. Medicare Part D Tiering. S.2129: Ensuring Access to Lower-Cost Medicines for Seniors Act. Medicare Reimbursement for Biosimilars. Medicaid Rebate Penalty. Rebates and Pharmacy Benefit Managers (PBMs). Medicare Price Negotiation. Medicare Advantage Proposed Rule. Inflation Reduction Act (IRA) Implementation.

LobbyistCovered position, as disclosed
CRAIG BURTON —
KARIN HESSLER —
PETER KELBEL —
KATHERINE RAAB —

Contacted: Natl Economic Council (NEC); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); SENATE

Bills named: S. 2129 (118th)

Copyright/Patent/Trademark CPT

Patent Settlements. Patent Abuse. Terminal Disclaimers/Obviousness-Type Double Patenting. Skinny Labeling. Hickenlooper Safe Harbor for Skinny Labeling. Inter Partes Review. Impact of IPR decisions on 30-month stay. IPR Amendments. Cornyn-Leahy IPR Proposals. Enhancing Quality of Patents through the PTAB. Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act. Patent Listings in Orange Book. H.R.1717/S.79: Interagency Patent Coordination and Improvement Act of 2023. S.142: Preserve Access to Affordable Generics and Biosimilars Act. S.148: Stop STALLING Act. S.150: Affordable Prescriptions for Patients Act of 2023. S.2140: A bill to amend title 35, United States Code, to address matters relating to patent subject matter eligibility, and for other purposes.

LobbyistCovered position, as disclosed
KARIN HESSLER —
PETER KELBEL —
KATHERINE RAAB —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: S. 150 (118th), H.R. 1717 (118th), S. 148 (118th), S. 79 (118th), S. 142 (118th), S. 2140 (118th)

Budget/Appropriations BUD

FDA Funding.

LobbyistCovered position, as disclosed
KARIN HESSLER —
PETER KELBEL —
KATHERINE RAAB —

Contacted: SENATE; Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES

Trade (domestic/foreign) TRD

General Trade Issues. Drug Supply Chain. AAM Blueprint to Enhance the Security of the U.S. Supply Chain. Trusted Partners in Medical Supply Chains.

LobbyistCovered position, as disclosed
KARIN HESSLER —
KATHERINE RAAB —

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Natl Economic Council (NEC)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.